Brief: Lantern Pharma Announces First Patient Dosed In The Phase 1 Study For Lp-184 In Advanced Solid Tumors
25/09/2023 13:36
Sept 25 (Reuters) - Lantern Pharma Inc LTRN.O :
* LANTERN PHARMA ANNOUNCES FIRST PATIENT DOSED IN THE PHASE
1
STUDY FOR LP-184 IN ADVANCED SOLID TUMORS
* LANTERN PHARMA INC- ANTICIPATES PHASE 1A PORTION OF TRIAL
TO BE
COMPLETED IN FIRST HALF OF 2024
Source text for Eikon: ID:nBw9Sc933a
Further company coverage: LTRN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lantern Pharma
See all newsBrief: Lantern Pharma Reports HARMONIC Data Showing LP-300 Progression-Free Survival Benefit Deepens With Treatment Duration In EGFR Exon 21 L858R Lung Cancer
Brief: Lantern Pharma Announces Successful Outcome Of FDA Type C Meeting Request For Harmonic Phase 2 Trial of LP-300 In Never-Smokers With NSCLC
Lantern Pharma Q1 net loss narrows on R&D cost cuts
Brief: Lantern Pharma Inc. Announces Up To $9.25 Million Registered Direct Offering With Existing Holders And A Single Institutional Investor
Brief: Lantern Pharma Inc - Schedules Type C FDA Meeting For Harmonic Protocol Amendments